Rituximab not be beneficial long-term in Sjorgen's Syndrome 2 Minute Medicine 1. The results of this study suggest that rituximab (Rituxin) treatment is not associated with a significant improvement in symptoms or disease activity at 6 months for patients with primary Sjogren syndrome (pSS). 2. There were transient improvements ... |
